Membranoproliferative Glomerulonephritis        SUMANEE PRAKOBSUK
Scopes Classification Pathophysiology Pathology Clinical features Treatment
Overview Also termed mesangiocapillary glomerulonephritis. MPGN accounts for approximately 7 to 10% of all cases of biop...
Classification          Idiopathic                        Secondary              Type I            Infection              ...
Classification Traditionally been classified into three subtypes   MPGN types I   MPGN types II   MPGN types III The ...
Type I : Subendothelial                                     depositsType II : Densedeposits in Laminadensa of GBMType III ...
Membranoproliferative Glomerulonephritis Type I Epidemiology  The   majority of patients with MPGN are children     betw...
IMMUNE-COMPLEX-MEDIATED MPGN      Pathogenesis MPGN typeI Results from the deposition of immune complexs in the glomeruli...
Secondary MPGN    Brenner&Rector’s: The Kidney 9th Edition
Pathogenesis of MPGN type I
Pathology of MPGN Type I LM    Mesagial proliferation    Endocapillary proliferation    Diffuse global capillary wall ...
Pathology of MPGN Type I LM    Mesangial interposition    Doubing or replication of     GBM                            ...
Pathology of MPGN Type IIF Granular staining for complement, especially C3, and usually immunoglobulins  (IgG or IGM) GB...
Pathology of MPGN Type IEM The ultrastructural  hallmark of type I Subendothelial Electron-  dense -deposits Mesangial ...
Clinical Features of MPGN typeI Nephrotic syndrome 40-70% Acute nephritic syndrome 25 % Asymptomatic proteinuria and he...
MembranoproliferativeMembranoproliferative Glomerulonephritis Type III Type III MPGN occurs in a very small number of chi...
Membranoproliferative Glomerulonephritis Type II                   Dense Deposit Disease Epidemiology    About 25% of MP...
Pathogenesis of MPGN type II (DDD) DDD is characterized by deposits of dense material  within the basement membranes of g...
Peter F. Zipfel*‡ and Christine Skerka*NATuRe RevIeWs Immunology vOLuMe 9 | OCTObeR 2009
Factor H Factor H
Pathogenesis of MPGN type II (DDD) Three distinct mechanisms result in uncontrolled activation of C3 convertase. 1 .The d...
Dysregulation of the alternative pathway
 To investigate causes for AP dysregulation 32 patients with DDD (renal Bx C3+ and    intramembranous electron-dense dep...
Results C3Nef detection assays:   25 patiests (78%) Factor H antoantibodies(FHAA)   1 patients (3%) Factor B autoanti...
Pathology :MPGN II( DDD)LM                                     5 distinct patterns:                         (1) Membranopr...
Pathology :MPGN II( DDD)          •Intense capillary wall linear to          bandlike staining for C3          •Little or ...
Pathology :MPGN II( DDD)A bandlike intramembranous dense deposit
Clinical Features :MPGN type II (DDD) ¾ of patients have all of the components of nephrotic syndrome on presentation. ¼ ...
Clinical Features :MPGN type II (DDD) May have deposits in the retina                         There is no correlation bet...
Clinical Features :MPGN type II (DDD) DDD may be associated with the syndrome of acquired partial lipodystrophy. About 8...
Prognosis:MPGN II (DDD) The prognosis for type II is worse than that for type I, worse in adults than in children. Clini...
Proposal for A new classification of MPGNProposal of a New classification Immune complex mediated MPGN. Complement media...
Semin Nephrol 31:341-348 © 2011
Treatment Based on the heterogeneity of cause and pattern of histologic injury of MPGN. All patients with MPGN must be t...
Treatment Idiopathic MPGN is now an uncommon condition. The few RCTs of treatment of idiopathic MPGN in children and adu...
Treatment Immunosuppressive agent   Prednisolone Cytotoxic agent   Cyclophosphamide   Mycophenolate Antiplatelet No...
 Double-blinded RCT. Compare altermate day prednisolone VS placebo Between February 1970 and October 1980              ...
Treatment of mesangiocapillary             glomerulonephritis        with alternate-day prednisone     Inclusion criteriaI...
Treatment of mesangiocapillary         glomerulonephritis    with alternate-day prednisone            • Prednisolone 40 mg...
61%                                                   P=0.07                                   12%Mean Tx 41 months       ...
Prednisolone for Idiopathic MPGN There has been no systematic evaluation of glucocorticoid therapy for idiopathic MPGN in...
Cytotoxic Agent Cyclophosphamide Mycophenolate
 RCT Compare  Combination   Cyclophosphamide   1.5-2.0 mg/dl   Coumadin keep PT 2-2.5 times   Dipyridamole start 25 ...
CycloInclusion        MPGN type I &II ( no crescent)        Proteinuria > 2 g/day        Ccr < 80 mI/mm.        Ruled out ...
BaselineMPGN Type I             Control(N =25)     Treatmemt (N=22)Age                        33 (6-70)           38 (12-7...
Change in Crcl /18 monthsMPGN Type I            MPGN Type II  P=0.4                    P=0.5                              ...
Proteinuria ,g/dayNo significant benefit could be observed over a period                    of 18 months.
 Retrospective analysis Treatment group   MMF started 500 mg/daymaximum 2 gm /day   Oral Prednisolone 60 mg/day , tap...
Change in proteinuria over timein control and MMF treated patients             P=0.03                          control    ...
Change in creatinine clearance over time in control and MMF treated patients.                                 MMF      P=0...
Antiplatelete Rationale  Demonstrations   of platelet activation and   deposition of platele antigen are invole in initi...
 Randomized,double blind placebo-controlled trial . Renal biopsy prove MPGN TypeI 1975-1981 Only 2 were receiveing the...
 Treatment   Dipyridamole 75 mg   Aspirin 325 mg   12 months Outcome   Treatment failure: decline of 25% Iotalamate ...
Pretreatment Clinical manifestations                   Treatment    Placebo                    N=21        N=19
Treatment failures(loss of renal function)                                       P<0.05           James V.Donadio,JR.Nejm1...
Change in Iothalamate clearance            -1.3 ml/min         -19.6 ml/min                                            P<0...
Platelet SurvivalJames V.Donadio,JR.Nejm1984;vol310(22)
 Follow up 7 years ESRD - 47 % in Placebo (33 months)        - 14 % in Treatment (62 months)GFR and was better maintaine...
PlasmapheresisCase report , improve renal function MPGN type II Rucurrent MPGN typeII post trasplant
Immunosuppressive drugsLevel of       Author   Design        N                Rx             Duration           Results/Co...
AntiplateletLevel     Author    Design                  Rx               Durati          Results/Commentsof evi           ...
Evidence based recommendations : KI 1999                                         Idiopathic MPGN                          ...
Pediatr Nephrol (2010) 25:1409–1418
Recurrence in KT 67-100% in MPGN II , graft loss 34-66% 20-33% in MPGN I Related to severity of previous disease > type...
 The Mayo Clinic Transplant database. On examination of the records of 1321 patients following  kidney transplant over a...
52 months of follow uprMPGN 12 /29 patients (41.4%)    Recurrence occurred during    first 14 months( Median 3.3 months)  ...
MPGN  Pam
MPGN  Pam
MPGN  Pam
MPGN  Pam
MPGN  Pam
MPGN  Pam
MPGN  Pam
Upcoming SlideShare
Loading in...5
×

MPGN Pam

1,733

Published on

Published in: Education, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
1,733
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
122
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

MPGN Pam

  1. 1. Membranoproliferative Glomerulonephritis SUMANEE PRAKOBSUK
  2. 2. Scopes Classification Pathophysiology Pathology Clinical features Treatment
  3. 3. Overview Also termed mesangiocapillary glomerulonephritis. MPGN accounts for approximately 7 to 10% of all cases of biopsy-confirmed glomerulonephritis. Brenner&Rector’s: The Kidney 9th Edition
  4. 4. Classification Idiopathic Secondary Type I Infection Hepatitis C and B Type II Visceral abscess Infectious endocarditis Type III Shunt nephritis Mycoplasma infection Rheumatologic disease SLE Scleroderna Sjogren syndrome Mixed essential cryoglobulinemia with or without hepatitis C infection Malignancy Carcinoma,Lymphoma,LeukemiaBrenner&Rectoer’s 9th Edition Complement deficiency Hereditary C2,C4 deficiency
  5. 5. Classification Traditionally been classified into three subtypes  MPGN types I  MPGN types II  MPGN types III The primary basis for this classification is histologic, the appearance of the capillary wall by electron microscopy and the location of electron-dense deposits. Brenner&Rector’s: The Kidney 9th Edition
  6. 6. Type I : Subendothelial depositsType II : Densedeposits in Laminadensa of GBMType III : Subendothelial&Subepithelial deposits
  7. 7. Membranoproliferative Glomerulonephritis Type I Epidemiology  The majority of patients with MPGN are children between the ages of 8 and 16 years.  The proportions of males and females with the disorder are nearly equal. Brenner&Rector’s: The Kidney 9th Edition
  8. 8. IMMUNE-COMPLEX-MEDIATED MPGN Pathogenesis MPGN typeI Results from the deposition of immune complexs in the glomeruli owing to persistent antigenemia. Type I MGPN often is secondary to recognizable causes. Brenner&Rector’s: The Kidney 9th Edition
  9. 9. Secondary MPGN Brenner&Rector’s: The Kidney 9th Edition
  10. 10. Pathogenesis of MPGN type I
  11. 11. Pathology of MPGN Type I LM  Mesagial proliferation  Endocapillary proliferation  Diffuse global capillary wall thickening “Lobular glomerulonephritis” Brenner&Rector’s: The Kidney 9th Edition
  12. 12. Pathology of MPGN Type I LM  Mesangial interposition  Doubing or replication of GBM Brenner&Rector’s: The Kidney 9th Edition
  13. 13. Pathology of MPGN Type IIF Granular staining for complement, especially C3, and usually immunoglobulins (IgG or IGM) GBM,Mesangial Few at TBM Brenner&Rector’s: The Kidney 9th Edition
  14. 14. Pathology of MPGN Type IEM The ultrastructural hallmark of type I Subendothelial Electron- dense -deposits Mesangial interposition Brenner&Rector’s: The Kidney 9th Edition
  15. 15. Clinical Features of MPGN typeI Nephrotic syndrome 40-70% Acute nephritic syndrome 25 % Asymptomatic proteinuria and hematuria 25 % HT (not severe) Renal insufficiency 50% Pediatr Nephrol.2010;25:1409-18.
  16. 16. MembranoproliferativeMembranoproliferative Glomerulonephritis Type III Type III MPGN occurs in a very small number of children and young adults. Clinical features of disease quite similar to those of type I MPGN. Regardless of the pathologic distinctions of MPGN type III ,few distinguishing clinical characteristics are noted in these patients. EM: subendothelial and subepithelial EDD Brenner&Rector’s: The Kidney 9th Edition
  17. 17. Membranoproliferative Glomerulonephritis Type II Dense Deposit Disease Epidemiology  About 25% of MPGN in children but is much less common in adults.  The large majority of patients are children 8 - 16 years.  2-3person/million.  Female:male = 3:2 J Am Soc Nephrol 16: 1392–1404, 2005 Brenner&Rector’s: The Kidney 9th Edition
  18. 18. Pathogenesis of MPGN type II (DDD) DDD is characterized by deposits of dense material within the basement membranes of glomeruli, Bowman’s capsule, and tubules. A porcine model of MPGN  Massive deposition of C3 and the terminal C5b9 complement complex (the membrane attack complex).  No immune complex deposits were detected in renal tissue. Dysregulation of alternative pathway. J Am Soc Nephrol 16: 1392–1404, 2005 Brenner&Rector’s: The Kidney 9th Edition
  19. 19. Peter F. Zipfel*‡ and Christine Skerka*NATuRe RevIeWs Immunology vOLuMe 9 | OCTObeR 2009
  20. 20. Factor H Factor H
  21. 21. Pathogenesis of MPGN type II (DDD) Three distinct mechanisms result in uncontrolled activation of C3 convertase. 1 .The development of an autoantibody, the C3 nephritic factor (C3NeF). - Protects C3 convertase form factor H. 2. The absence of circulating factor H . 3. The presence of a circulating inhibitor of factorH. Brenner&Rector’s: The Kidney 9th Edition
  22. 22. Dysregulation of the alternative pathway
  23. 23.  To investigate causes for AP dysregulation 32 patients with DDD (renal Bx C3+ and intramembranous electron-dense deposits by EM) C3Nef detection assays Factor H antoantibodies(FHAA) Factor B autoantibodies (FBAA) Factor H Mutation screening.
  24. 24. Results C3Nef detection assays:  25 patiests (78%) Factor H antoantibodies(FHAA)  1 patients (3%) Factor B autoantibodies (FBAA)  3 patiests (9%) Factor H Mutation screening.  26 patiests(81%) carried at least one copy of the FH His402 polymorphism.
  25. 25. Pathology :MPGN II( DDD)LM 5 distinct patterns: (1) Membranoproliferative pattern (2) Mesangioproliferative pattern (3) Crescentic pattern (4) Acute proliferative and exudative pattern (5) Unclassified dense deposit disease. Sibley RK, Kim Y. Dense intramembranous deposit disease: new pathologic features. Kidney Int. 1984;25:660-670.
  26. 26. Pathology :MPGN II( DDD) •Intense capillary wall linear to bandlike staining for C3 •Little or no staining for Ig
  27. 27. Pathology :MPGN II( DDD)A bandlike intramembranous dense deposit
  28. 28. Clinical Features :MPGN type II (DDD) ¾ of patients have all of the components of nephrotic syndrome on presentation. ¼ of patients have acute nephritic syndrome. HT is typically mild, but may be severe in some cases. Renal dysfunction occurs in at least half of cases and is more common in adults han in children. Brenner&Rector’s: The Kidney 9th Edition
  29. 29. Clinical Features :MPGN type II (DDD) May have deposits in the retina There is no correlation between the severity of kidney and ocular involvement. J Am Soc Nephrol 16: 1392–1404, 2005
  30. 30. Clinical Features :MPGN type II (DDD) DDD may be associated with the syndrome of acquired partial lipodystrophy. About 80% of patients with this syndrome have low C3 levels and C3NeF. About 20% of patientsdevelop MPGN
  31. 31. Prognosis:MPGN II (DDD) The prognosis for type II is worse than that for type I, worse in adults than in children. Clinical remissions are rare,occurring in fewer than 5% of children. Patients generally reach ESRD in 8 to 12 years from the onset of disease. Brenner&Rector’s: The Kidney 9th Edition
  32. 32. Proposal for A new classification of MPGNProposal of a New classification Immune complex mediated MPGN. Complement mediated MPGN. Sanjeev Sethi, Fernando C. Semin Nephrol 31:341-348 © 2011
  33. 33. Semin Nephrol 31:341-348 © 2011
  34. 34. Treatment Based on the heterogeneity of cause and pattern of histologic injury of MPGN. All patients with MPGN must be thoroughly evaluated for underlying diseases before classifying as idiopathic MPGN, and before any specific treatment decisions can be made. When there is a secondary MPGN, treatment should be directed against that cause
  35. 35. Treatment Idiopathic MPGN is now an uncommon condition. The few RCTs of treatment of idiopathic MPGN in children and adults have given inconsistent and largely inconclusive results . Many of the reported trials have weak experimental design or are underpowered, and the evidence base underlying the recommendations for treatment of “idiopathic” MPGN is very weak.
  36. 36. Treatment Immunosuppressive agent  Prednisolone Cytotoxic agent  Cyclophosphamide  Mycophenolate Antiplatelet Non-specific Tx
  37. 37.  Double-blinded RCT. Compare altermate day prednisolone VS placebo Between February 1970 and October 1980 Pediatr Nephrol(1992)6:123-130
  38. 38. Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone Inclusion criteriaInclusion criteria 1. Biopsy-prove MCGN 2. GFR by crcl ≥ 70 ml/min per 1.73 m 2 3. Heavy proteinuria ≥ 40 mg/h per m 2 4. No evidence of SLE, HSP, nephritis accompanying bacteremia (such as IE), or malaria, 5. No treatment with corticosteroids during the year prior to entry into the trial or with immunosuppressive agents at any time. Pediatr Nephrol(1992)6:123-130
  39. 39. Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone • Prednisolone 40 mg/m2 alternate daysTreatment • Maximum dose 60 mg • 5 years • Treatment failure: increase from baseline in serum creatinine of 30% or more, or more than 0.4 mg/dl.Outcome • Renal failure : cr ≥ 4 mg/dl • Stable: no change or increase in S.Cr <0.4 mg/dl Pediatr Nephrol(1992)6:123-130
  40. 40. 61% P=0.07 12%Mean Tx 41 months Alternate- day prednisone therapyTreatment failure improves the prognosis of Treatment 40% patients with MCGN, when used at doses control 54% of 40 mg/m2.
  41. 41. Prednisolone for Idiopathic MPGN There has been no systematic evaluation of glucocorticoid therapy for idiopathic MPGN in adults. Retrospective studies showed no clear benefit from glucocorticoid therapy, but treatment was not as prolonged in adults as it was in children. Kidney International,Vol55(1999)pps41-s46
  42. 42. Cytotoxic Agent Cyclophosphamide Mycophenolate
  43. 43.  RCT Compare  Combination Cyclophosphamide 1.5-2.0 mg/dl Coumadin keep PT 2-2.5 times Dipyridamole start 25 mg qid  full dose 100 mg qid  No specific therapy
  44. 44. CycloInclusion MPGN type I &II ( no crescent) Proteinuria > 2 g/day Ccr < 80 mI/mm. Ruled out Secondary causes of MPGNExclusion Active infectin Previous tuberculosis, Hx PU Uncontrolled HTOutcome Change of crcl from baseline at 18 months
  45. 45. BaselineMPGN Type I Control(N =25) Treatmemt (N=22)Age 33 (6-70) 38 (12-77)Crcl (ml/min/1.73 m2) 64 (18-135) 65 (16-113)Cr (mg/dl) 1.8 (0.7-7.0) 1.7 (0.7-5.9)Proteinuria ( g/day) 5.2 (0.85-16.4) 3.6(0.4-8.3)MPGN Type II Control(N =7) Treatmemt (N=5)Age 19(7-58) 17.5 (6-26)Crcl (ml/min/1.73 m2) 87 (51-131) 63 (37-115)Cr (mg/dl) 0.9 (0.3-1.2) 1.2 (0.7-2.1)Proteinuria ( g/day) 4.3 (0.1-11.7) 6.8 (1.7-12.8)
  46. 46. Change in Crcl /18 monthsMPGN Type I MPGN Type II P=0.4 P=0.5 -1 0 -14 -8
  47. 47. Proteinuria ,g/dayNo significant benefit could be observed over a period of 18 months.
  48. 48.  Retrospective analysis Treatment group  MMF started 500 mg/daymaximum 2 gm /day  Oral Prednisolone 60 mg/day , tapering to 20mg within 2 months and withdrawn by 1 year. Control group  Did not receive immunosuppressive therapy
  49. 49. Change in proteinuria over timein control and MMF treated patients P=0.03 control MMF
  50. 50. Change in creatinine clearance over time in control and MMF treated patients. MMF P=0.06 control
  51. 51. Antiplatelete Rationale  Demonstrations of platelet activation and deposition of platele antigen are invole in initiating or contributing to glomerular injury . Glomerular prostaglandin and thromboxane systesis in rat nephrotoxic serum nephritis.J Clin Invest 1983;72:1439-48
  52. 52.  Randomized,double blind placebo-controlled trial . Renal biopsy prove MPGN TypeI 1975-1981 Only 2 were receiveing therapy with prednisolone,with discontinued at the time of entry None had been treated with cytotoxic drugs. Excluded  SLE,essential mixed cryoglobulinemia,PIGN,dialysis James V.Donadio,JR.Nejm1984;vol310(22)
  53. 53.  Treatment  Dipyridamole 75 mg  Aspirin 325 mg  12 months Outcome  Treatment failure: decline of 25% Iotalamate clearance from pre treatment. James V.Donadio,JR.Nejm1984;vol310(22)
  54. 54. Pretreatment Clinical manifestations Treatment Placebo N=21 N=19
  55. 55. Treatment failures(loss of renal function) P<0.05 James V.Donadio,JR.Nejm1984;vol310(22)
  56. 56. Change in Iothalamate clearance -1.3 ml/min -19.6 ml/min P<0.02 No differences between the groups Proteinuria,Amount of RBC cast, C3,C4,CH50 James V.Donadio,JR.Nejm1984;vol310(22)
  57. 57. Platelet SurvivalJames V.Donadio,JR.Nejm1984;vol310(22)
  58. 58.  Follow up 7 years ESRD - 47 % in Placebo (33 months) - 14 % in Treatment (62 months)GFR and was better maintained, and progression toESRD occurred less often and over a longer period,inthe group treated with platelet-inhibitor drugs thanin the group given placebo James V.Donadio,JR.Nejm1984;vol310(22)
  59. 59. PlasmapheresisCase report , improve renal function MPGN type II Rucurrent MPGN typeII post trasplant
  60. 60. Immunosuppressive drugsLevel of Author Design N Rx Duration Results/CommentsEvidence [Rx : C]1 Tarshish RCT 80 [47/33] Pred 40 mg/m2 130 mo Children only, predomly MPGN I, stable renal fn AD vs pcb Pred 61% [Rx] vs 12% [C] No difference found,1 Cattran RCT 59 CY + coumadin 18 mo [27/32] + dipyridamole mixed MPGN I > II CY vs No Rx 19853 Strife UCT 17 Pred 2 mk AD 2y MPGN III only, nephrotic range [16/1] did worse, 3/16 dvled RF3 Davis CT 27 Pred+IS [NS] - No effect [19/8]3 Orlowski UCT 50 P/AZA/CP/chlorambucil 79 mo 10 y F/U, ↓ Uprot c triple drug in combi Rx3 Ford UCT 19 PO/IV pred 2 mk + 8-10 wk, Children; 6.5 y F/U, early Rx, ACEI then x2-3 shorter course, y tapered ↓ glom prolif dose3 Faedda UCT 19 IV/PO CY+P 10 mo 15/19 remission, 7 y F/U 1994 [different combinations] Adeera Levin., Mx of MPGN; Evidence based recommendations; KI 1999; 55: S41-S46
  61. 61. AntiplateletLevel Author Design Rx Durati Results/Commentsof evi N [Rx : C] on1 Donadio 1984 RCT Dipyridamole 75mg/d + ASA 325 12 mo -Tx : significantly delay rate of GFR ↓ Prospective mg/d vs Pcb [Sig difference at 7 y] 40 [21/19] -No change in Uprot, hematuria, Complement -Mild bleeding complication required discontinuation 15%1 Zimmer man RCT Warfarin [INR 1.5-2] + dipyridamole [75-100 12 mo [2 y Prot restriction & HTN control standardized. Crossover mg qid] vs Pcb study] Sig reduction in proturia 18 [8/10] NS diff in renal fn Significantly ↓ Uprot1 Zauner 1994 RCT ASA 500 mg/d + dipyridamole 75 36 mo [1 g Tx vs 8 g control] [Sig] 18 [9/9] mg/d PR : Tx 7/10 vs Control [I 15 + III [both : prot restriction 2/8 3] & HTN control] -Comment : short F/U SCr 1.8, Uprot 7 g/d Adeera Levin., Mx of MPGN; Evidence based recommendations; KI 1999; 55: S41-S46
  62. 62. Evidence based recommendations : KI 1999 Idiopathic MPGN 24 h Uprot & CCr <3 g >3 g Normal renal function Abn renal function Normal renal function Abn renal fn Grade C; Grade A; Grade B; Child : trial of steroid x 3 Child : trial of Adult : trial of ASA mo [AD; IV or PO 1 mk] steroids 40 mg/m2 325 mg/d & Or AD x 6-12 mo Dipyridamole 75-100 Adult : no Rx, observe mg tid x 6-12 mo F/U q 3 mo; BP, Lipid monitoring -No change : continued F/U, ↓ frequency - Increase cr or proteinuria  Rx Adeera Levin., Mx of MPGN; Evidence based recommendations; KI 1999; 55: S41-S46
  63. 63. Pediatr Nephrol (2010) 25:1409–1418
  64. 64. Recurrence in KT 67-100% in MPGN II , graft loss 34-66% 20-33% in MPGN I Related to severity of previous disease > type of MPGN.
  65. 65.  The Mayo Clinic Transplant database. On examination of the records of 1321 patients following kidney transplant over an 11-year period 29 patients of MPGN Excluded MPGN type II, secondary MPGN Follow up Protocal Bx 0,4,12,24,60 months Kidney International (2010) 77, 721–728
  66. 66. 52 months of follow uprMPGN 12 /29 patients (41.4%) Recurrence occurred during first 14 months( Median 3.3 months) Kidney International (2010) 77, 721–728
  1. ¿Le ha llamado la atención una diapositiva en particular?

    Recortar diapositivas es una manera útil de recopilar información importante para consultarla más tarde.

×